Patents by Inventor Ishan Capila

Ishan Capila has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190048417
    Abstract: The present invention features methods of treating a subject having an autoimmune disease and/or inflammation including determining the genotype, and/or the glycophenotype of the subject and administering to the subject an Fc-activity modulating agent or an anti-TNF? agent based on the genotype and/or the glycophenotype of the subject. The invention also features methods of predicting the responsiveness of a patient to an anti-TNF? treatment by identifying a patient having inflammation or an autoimmune disease, determining the genotype, or glycophenotype of the subject, and selecting the patient for treatment with an Fc-activity modulating agent or an anti-TNF? agent based on the genotype and/or the glycophenotype of the subject.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 14, 2019
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Nathaniel Washburn, Patrick Halvey, Kevin McConnell, Victor Farutin, Ishan Capila, Leona E. Ling, Anthony Manning
  • Patent number: 9068957
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 30, 2015
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Nur Sibel Gunay, Miroslaw Lech, Sucharita Roy, John Schaeck, Jennifer Ozug, Daniela Beccati, Ishan Capila
  • Publication number: 20150099001
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
    Type: Application
    Filed: September 8, 2014
    Publication date: April 9, 2015
    Inventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan
  • Publication number: 20140363497
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
    Type: Application
    Filed: August 25, 2014
    Publication date: December 11, 2014
    Inventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan
  • Publication number: 20140114056
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.
    Type: Application
    Filed: February 21, 2012
    Publication date: April 24, 2014
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Nur Sibel Gunay, Miroslaw Lech, Sucharita Roy, John Schaeck, Jennifer Ozug, Daniela Beccati, Ishan Capila
  • Patent number: 8617896
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using fast performance liquid chromatography (FPLC) and high liquid performance chromatography (HPLC), e.g., strong anion exchange HPLC.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 31, 2013
    Inventors: Zachary Shriver, Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Jennifer Ozug, Steve Wudyka
  • Patent number: 8609632
    Abstract: Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: December 17, 2013
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Mallikarjun Sundaram, Ganesh Venkataraman, Pat Oliver-Shaffer, Yiming Yao, Zainab Sirajbhai Mamuwala, Ian David Fier, Yiwei Qi, Ishan Capila, Nur Sibel Gunay, Daniela Beccati, Cuihua Liu, Corinne Bauer, Ying Li
  • Patent number: 8435795
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature that is indicative of the methods used to make the heparin preparation.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: May 7, 2013
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Sucharita Roy
  • Patent number: 8338119
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: December 25, 2012
    Assignee: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Patent number: 8252597
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using fast performance liquid chromatography (FPLC) and high liquid performance chromatography (HPLC), e.g., strong anion exchange HPLC.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: August 28, 2012
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Jennifer Ozug, Steve Wudyka
  • Patent number: 8101733
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin or a LMWH, using reduce end labeling are described. In general, the mixture of polysaccharides includes polysaccharides having a desired structural moiety. In some instances, one or more polysaccharides in the mixture are chemically modified prior to analysis.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: January 24, 2012
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Cuihua Liu, Nur Sibel Gunay, Ishan Capila, Ganesh Venkataraman
  • Patent number: 8076149
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using fast performance liquid chromatography (FPLC) and high liquid performance chromatography (HPLC), e.g., strong anion exchange HPLC.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: December 13, 2011
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Jennifer Ozug, Steve Wudyka
  • Publication number: 20110207919
    Abstract: Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature that is indicative of the methods used to make the heparin preparation.
    Type: Application
    Filed: January 18, 2011
    Publication date: August 25, 2011
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Sucharita Roy
  • Patent number: 7968082
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as enoxaparin are described. In some instances, the mixtures are analyzed using 1D NMR and/or 2D NMR.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: June 28, 2011
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Daniela Beccati, Ishan Capila, Jonathan Lansing
  • Publication number: 20100303912
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
    Type: Application
    Filed: May 14, 2010
    Publication date: December 2, 2010
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan
  • Publication number: 20100305022
    Abstract: Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 2, 2010
    Inventors: Zachary Shriver, Mallikarjun Sundaram, Ganesh Venkataraman, Pat Oliver-Shaffer, Yiming Yao, Zainab Sirajbhai Mamuwala, Ian David Fier, Yiwei Qi, Ishan Capila, Nur Sibel Gunay, Daniela Beccati, Cuihua Liu, Corinne Bauer, Ying Li
  • Publication number: 20100272822
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antiangiogenic agent.
    Type: Application
    Filed: June 4, 2010
    Publication date: October 28, 2010
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: SHILADITYA SENGUPTA, GANLIN ZHAO, ISHAN CAPILA, DAVID EAVARONE, RAM SASISEKHARAN
  • Patent number: 7816144
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using fast performance liquid chromatography (FPLC) and high liquid performance chromatography (HPLC), e.g., strong anion exchange HPLC.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: October 19, 2010
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Jennifer Ozug, Steve Wudyka
  • Patent number: 7790466
    Abstract: Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using fast performance liquid chromatography (FPLC) and high liquid performance chromatography (HPLC), e.g., strong anion exchange HPLC.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: September 7, 2010
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Zachary Shriver, Daniela Beccati, Ishan Capila, Nur Sibel Gunay, Jennifer Ozug, Steve Wudyka
  • Patent number: 7662604
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: February 16, 2010
    Assignee: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan